FDA's Drugs@FDA database recorded a supplement dated 24 September to an abbreviated new drug application (ANDA076440) held by ANI Pharmaceuticals for generic risperidone. The record does not state what the supplement changed.
Supplements to generic applications are routine: they usually cover manufacturing, packaging or labelling updates aligned to the reference product. Nothing in the record indicates a new safety concern, a new indication, or any change to how risperidone should be prescribed.
Risperidone is widely available as a generic in India, and this action has no bearing on Indian supply or CDSCO's position.
- Make no change to risperidone prescribing on the strength of this record.
- Read a generic supplement as an administrative change unless FDA issues a safety communication alongside it.
- Keep monitoring for prolactin, metabolic and extrapyramidal effects as usual.
- Check FDA safety communications, not application supplements, for new risperidone warnings.
Why it matters
It shows how much of the regulatory feed is housekeeping, and why the wording of an action matters.
Don't overread it
A supplement to a generic application is not a safety finding or a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free